MdmX is a substrate for the deubiquitinating enzyme USP2a

N. Allende-Vega, A. Sparks, D. P. Lane, M. K. Saville (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    60 Citations (Scopus)

    Abstract

    It has previously been shown that ubiquitin-specific protease 2a (USP2a) is a regulator of the Mdm2/p53 pathway. USP2a binds to Mdm2 and can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination. Overexpression of USP2a causes accumulation of Mdm2 and promotes p53 degradation. We now show that MdmX is also a substrate for USP2a. MdmX associates with USP2a independently of Mdm2. Ectopic expression of wild-type USP2a but not a catalytic mutant prevents Mdm2-mediated degradation of MdmX. This correlates with the ability of wild-type USP2a to deubiquitinate MdmX. siRNA-mediated knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells causes destabilization of MdmX and results in a decrease in MdmX protein levels, showing that endogenous USP2a participates in the regulation of MdmX stability. The therapeutic drug, cisplatin decreases MdmX protein expression. USP2a mRNA and protein levels were also reduced after cisplatin exposure. The magnitude and time course of USP2a downregulation suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin. Knockdown of USP2a increases the sensitivity of NTERA-2 cells to cisplatin, raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy. Oncogene (2010) 29, 432-441; doi:10.1038/onc.2009.330; published online 19 October 2009

    Original languageEnglish
    Pages (from-to)432-441
    Number of pages10
    JournalOncogene
    Volume29
    Issue number3
    DOIs
    Publication statusPublished - 21 Jan 2010

    Keywords

    • USP2a
    • MdmX
    • Mdm2
    • p53
    • ubiquitin
    • deubiquitinating enzyme
    • P53 ACTIVATION
    • DNA-DAMAGE
    • IN-VIVO
    • EMBRYONIC LETHALITY
    • UBIQUITIN LIGASE
    • PROSTATE-CANCER
    • TARGETING MDM2
    • CISPLATIN
    • CELLS
    • PATHWAY

    Cite this

    Allende-Vega, N., Sparks, A., Lane, D. P., & Saville, M. K. (2010). MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene, 29(3), 432-441. https://doi.org/10.1038/onc.2009.330
    Allende-Vega, N. ; Sparks, A. ; Lane, D. P. ; Saville, M. K. / MdmX is a substrate for the deubiquitinating enzyme USP2a. In: Oncogene. 2010 ; Vol. 29, No. 3. pp. 432-441.
    @article{09a3b35842144a4ab823fe360eb6e4e1,
    title = "MdmX is a substrate for the deubiquitinating enzyme USP2a",
    abstract = "It has previously been shown that ubiquitin-specific protease 2a (USP2a) is a regulator of the Mdm2/p53 pathway. USP2a binds to Mdm2 and can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination. Overexpression of USP2a causes accumulation of Mdm2 and promotes p53 degradation. We now show that MdmX is also a substrate for USP2a. MdmX associates with USP2a independently of Mdm2. Ectopic expression of wild-type USP2a but not a catalytic mutant prevents Mdm2-mediated degradation of MdmX. This correlates with the ability of wild-type USP2a to deubiquitinate MdmX. siRNA-mediated knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells causes destabilization of MdmX and results in a decrease in MdmX protein levels, showing that endogenous USP2a participates in the regulation of MdmX stability. The therapeutic drug, cisplatin decreases MdmX protein expression. USP2a mRNA and protein levels were also reduced after cisplatin exposure. The magnitude and time course of USP2a downregulation suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin. Knockdown of USP2a increases the sensitivity of NTERA-2 cells to cisplatin, raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy. Oncogene (2010) 29, 432-441; doi:10.1038/onc.2009.330; published online 19 October 2009",
    keywords = "USP2a, MdmX, Mdm2, p53, ubiquitin, deubiquitinating enzyme, P53 ACTIVATION, DNA-DAMAGE, IN-VIVO, EMBRYONIC LETHALITY, UBIQUITIN LIGASE, PROSTATE-CANCER, TARGETING MDM2, CISPLATIN, CELLS, PATHWAY",
    author = "N. Allende-Vega and A. Sparks and Lane, {D. P.} and Saville, {M. K.}",
    year = "2010",
    month = "1",
    day = "21",
    doi = "10.1038/onc.2009.330",
    language = "English",
    volume = "29",
    pages = "432--441",
    journal = "Oncogene",
    issn = "0950-9232",
    publisher = "Nature Publishing Group",
    number = "3",

    }

    Allende-Vega, N, Sparks, A, Lane, DP & Saville, MK 2010, 'MdmX is a substrate for the deubiquitinating enzyme USP2a', Oncogene, vol. 29, no. 3, pp. 432-441. https://doi.org/10.1038/onc.2009.330

    MdmX is a substrate for the deubiquitinating enzyme USP2a. / Allende-Vega, N.; Sparks, A.; Lane, D. P.; Saville, M. K. (Lead / Corresponding author).

    In: Oncogene, Vol. 29, No. 3, 21.01.2010, p. 432-441.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - MdmX is a substrate for the deubiquitinating enzyme USP2a

    AU - Allende-Vega, N.

    AU - Sparks, A.

    AU - Lane, D. P.

    AU - Saville, M. K.

    PY - 2010/1/21

    Y1 - 2010/1/21

    N2 - It has previously been shown that ubiquitin-specific protease 2a (USP2a) is a regulator of the Mdm2/p53 pathway. USP2a binds to Mdm2 and can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination. Overexpression of USP2a causes accumulation of Mdm2 and promotes p53 degradation. We now show that MdmX is also a substrate for USP2a. MdmX associates with USP2a independently of Mdm2. Ectopic expression of wild-type USP2a but not a catalytic mutant prevents Mdm2-mediated degradation of MdmX. This correlates with the ability of wild-type USP2a to deubiquitinate MdmX. siRNA-mediated knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells causes destabilization of MdmX and results in a decrease in MdmX protein levels, showing that endogenous USP2a participates in the regulation of MdmX stability. The therapeutic drug, cisplatin decreases MdmX protein expression. USP2a mRNA and protein levels were also reduced after cisplatin exposure. The magnitude and time course of USP2a downregulation suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin. Knockdown of USP2a increases the sensitivity of NTERA-2 cells to cisplatin, raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy. Oncogene (2010) 29, 432-441; doi:10.1038/onc.2009.330; published online 19 October 2009

    AB - It has previously been shown that ubiquitin-specific protease 2a (USP2a) is a regulator of the Mdm2/p53 pathway. USP2a binds to Mdm2 and can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination. Overexpression of USP2a causes accumulation of Mdm2 and promotes p53 degradation. We now show that MdmX is also a substrate for USP2a. MdmX associates with USP2a independently of Mdm2. Ectopic expression of wild-type USP2a but not a catalytic mutant prevents Mdm2-mediated degradation of MdmX. This correlates with the ability of wild-type USP2a to deubiquitinate MdmX. siRNA-mediated knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells causes destabilization of MdmX and results in a decrease in MdmX protein levels, showing that endogenous USP2a participates in the regulation of MdmX stability. The therapeutic drug, cisplatin decreases MdmX protein expression. USP2a mRNA and protein levels were also reduced after cisplatin exposure. The magnitude and time course of USP2a downregulation suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin. Knockdown of USP2a increases the sensitivity of NTERA-2 cells to cisplatin, raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy. Oncogene (2010) 29, 432-441; doi:10.1038/onc.2009.330; published online 19 October 2009

    KW - USP2a

    KW - MdmX

    KW - Mdm2

    KW - p53

    KW - ubiquitin

    KW - deubiquitinating enzyme

    KW - P53 ACTIVATION

    KW - DNA-DAMAGE

    KW - IN-VIVO

    KW - EMBRYONIC LETHALITY

    KW - UBIQUITIN LIGASE

    KW - PROSTATE-CANCER

    KW - TARGETING MDM2

    KW - CISPLATIN

    KW - CELLS

    KW - PATHWAY

    UR - http://www.scopus.com/inward/record.url?scp=75149174149&partnerID=8YFLogxK

    U2 - 10.1038/onc.2009.330

    DO - 10.1038/onc.2009.330

    M3 - Article

    C2 - 19838211

    VL - 29

    SP - 432

    EP - 441

    JO - Oncogene

    JF - Oncogene

    SN - 0950-9232

    IS - 3

    ER -

    Allende-Vega N, Sparks A, Lane DP, Saville MK. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene. 2010 Jan 21;29(3):432-441. https://doi.org/10.1038/onc.2009.330